Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.06
NAS:KERX's Cash to Debt is ranked lower than
80% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:KERX: 1.06 )
Ranked among companies with meaningful Cash to Debt only.
NAS:KERX' s Cash to Debt Range Over the Past 10 Years
Min: 0.62  Med: No Debt Max: No Debt
Current: 1.06
Equity to Asset 0.13
NAS:KERX's Equity to Asset is ranked lower than
89% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:KERX: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
NAS:KERX' s Equity to Asset Range Over the Past 10 Years
Min: -0.06  Med: 0.82 Max: 0.93
Current: 0.13
-0.06
0.93
F-Score: 3
Z-Score: -6.25
M-Score: 65.00
WACC vs ROIC
25.86%
-379.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -404.88
NAS:KERX's Operating margin (%) is ranked lower than
67% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:KERX: -404.88 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:KERX' s Operating margin (%) Range Over the Past 10 Years
Min: -15010.67  Med: -919.71 Max: 38.97
Current: -404.88
-15010.67
38.97
Net-margin (%) -584.76
NAS:KERX's Net-margin (%) is ranked lower than
72% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:KERX: -584.76 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:KERX' s Net-margin (%) Range Over the Past 10 Years
Min: -13813.48  Med: -965.19 Max: 41.62
Current: -584.76
-13813.48
41.62
ROE (%) -243.33
NAS:KERX's ROE (%) is ranked lower than
93% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:KERX: -243.33 )
Ranked among companies with meaningful ROE (%) only.
NAS:KERX' s ROE (%) Range Over the Past 10 Years
Min: -246.34  Med: -108.23 Max: 68.51
Current: -243.33
-246.34
68.51
ROA (%) -80.68
NAS:KERX's ROA (%) is ranked lower than
82% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:KERX: -80.68 )
Ranked among companies with meaningful ROA (%) only.
NAS:KERX' s ROA (%) Range Over the Past 10 Years
Min: -135.67  Med: -73.82 Max: 31.09
Current: -80.68
-135.67
31.09
ROC (Joel Greenblatt) (%) -294.95
NAS:KERX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:KERX: -294.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:KERX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -46369.35  Med: -7601.85 Max: 7114.49
Current: -294.95
-46369.35
7114.49
EBITDA Growth (3Y)(%) 41.40
NAS:KERX's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:KERX: 41.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:KERX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.1  Med: 17.4 Max: 70.9
Current: 41.4
-45.1
70.9
EPS Growth (3Y)(%) 49.80
NAS:KERX's EPS Growth (3Y)(%) is ranked higher than
91% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:KERX: 49.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:KERX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.7  Med: 17.1 Max: 60.5
Current: 49.8
-44.7
60.5
» NAS:KERX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

KERX Guru Trades in Q4 2015

Chuck Royce 341,725 sh (New)
Paul Tudor Jones 44,597 sh (+217.01%)
David Abrams 5,500,000 sh (+10.00%)
Seth Klarman 25,791,678 sh (unchged)
» More
Q1 2016

KERX Guru Trades in Q1 2016

Joel Greenblatt 25,457 sh (New)
Chuck Royce 451,725 sh (+32.19%)
David Abrams 5,719,176 sh (+3.99%)
Seth Klarman 25,791,678 sh (unchged)
Paul Tudor Jones 30,106 sh (-32.49%)
» More
Q2 2016

KERX Guru Trades in Q2 2016

Joel Greenblatt 77,976 sh (+206.30%)
Paul Tudor Jones 30,687 sh (+1.93%)
Chuck Royce 451,725 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Seth Klarman 25,791,678 sh (unchged)
» More
Q3 2016

KERX Guru Trades in Q3 2016

David Abrams 5,719,176 sh (unchged)
Seth Klarman 25,791,678 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 317,725 sh (-29.66%)
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:LOXO, NAS:EPZM, NAS:ANIK, NAS:GBT, NAS:CLCD, NAS:ANIP, NAS:NTLA, NAS:NK, NAS:PGNX, NAS:VTAE, NAS:ACHN, OTCPK:SNBIF, NAS:ACRS, NAS:CERS, NAS:ITCI, NAS:RGNX, NAS:ARDX, NAS:PACB, NAS:AMRI, OTCPK:PHMMF » details
Traded in other countries:KYX.Germany,
Keryx Biopharmaceuticals Inc is a biopharmaceutical company focused on therapies for patients with renal disease. Its first product is the AuryxiaTM (ferric citrate), an oral, absorbable iron-based compound.

Keryx Biopharmaceuticals Inc was incorporated in Delaware in October 1998. It is a biopharmaceutical company focused on therapies for patients with renal disease. Its product AuryxiaTM, also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound approved for the control of serum phosphorus levels in patients with CKD on dialysis.

Top Ranked Articles about Keryx Biopharmaceuticals Inc

Klarman Gives Insight on Keryx Biopharmaceuticals Investment Guru has confidence in sole FDA-approved product
Back in November, I tried to guess Seth Klarman's (Trades, Portfolio) motives for investing in Keryx Biopharmaceuticals (NASDAQ:KERX), an unusual biotech position for the renowned value investor. In his latest letter to shareholder, the secretive guru has finally commented on this company. In November I wrote: Read more...
Seth Klarman Blames Market, Investments for Rare Down Year Klarman discusses third down year in fund's history
One of the most widely followed and profitable value investors, Seth Klarman (Trades, Portfolio) told clients that in 2015 his firm Baupost Group lost money for the third year in its history. Read more...

Ratios

vs
industry
vs
history
P/B 29.15
KERX's P/B is ranked lower than
95% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. KERX: 29.15 )
Ranked among companies with meaningful P/B only.
KERX' s P/B Range Over the Past 10 Years
Min: 1.85  Med: 7.01 Max: 68.57
Current: 29.15
1.85
68.57
P/S 22.52
KERX's P/S is ranked lower than
65% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. KERX: 22.52 )
Ranked among companies with meaningful P/S only.
KERX' s P/S Range Over the Past 10 Years
Min: 1.18  Med: 63.73 Max: 2228
Current: 22.52
1.18
2228
Current Ratio 8.75
KERX's Current Ratio is ranked higher than
73% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. KERX: 8.75 )
Ranked among companies with meaningful Current Ratio only.
KERX' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 7.47 Max: 106.93
Current: 8.75
1.88
106.93
Quick Ratio 7.42
KERX's Quick Ratio is ranked higher than
69% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. KERX: 7.42 )
Ranked among companies with meaningful Quick Ratio only.
KERX' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 7.07 Max: 106.93
Current: 7.42
1.88
106.93
Days Inventory 479.12
KERX's Days Inventory is ranked lower than
94% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. KERX: 479.12 )
Ranked among companies with meaningful Days Inventory only.
KERX' s Days Inventory Range Over the Past 10 Years
Min: 479.12  Med: 2126.15 Max: 2886.82
Current: 479.12
479.12
2886.82
Days Sales Outstanding 65.95
KERX's Days Sales Outstanding is ranked lower than
54% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. KERX: 65.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
KERX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.51  Med: 28.12 Max: 1399.85
Current: 65.95
0.51
1399.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.50
KERX's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. KERX: -13.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KERX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.8  Med: -12.1 Max: -6.3
Current: -13.5
-34.8
-6.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 45.38
KERX's Price/Net Current Asset Value is ranked lower than
94% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. KERX: 45.38 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KERX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.07  Med: 7.33 Max: 46.08
Current: 45.38
1.07
46.08
Price/Tangible Book 32.78
KERX's Price/Tangible Book is ranked lower than
94% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. KERX: 32.78 )
Ranked among companies with meaningful Price/Tangible Book only.
KERX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.93  Med: 6.42 Max: 33.28
Current: 32.78
0.93
33.28
Price/Median PS Value 0.34
KERX's Price/Median PS Value is ranked higher than
87% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. KERX: 0.34 )
Ranked among companies with meaningful Price/Median PS Value only.
KERX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 1.81 Max: 80.42
Current: 0.34
0.02
80.42
Earnings Yield (Greenblatt) (%) -18.12
KERX's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. KERX: -18.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KERX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -19.4  Med: 191.2 Max: 27616.5
Current: -18.12
-19.4
27616.5

More Statistics

Revenue (TTM) (Mil) $28.23
EPS (TTM) $ -1.56
Beta3.14
Short Percentage of Float27.61%
52-Week Range $2.80 - 7.80
Shares Outstanding (Mil)105.96

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 30 63 151 271
EPS ($) -1.32 -0.16 0.35 0.98
EPS w/o NRI ($) -1.32 -0.16 0.35 0.98
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for KERX

Headlines

Articles On GuruFocus.com
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
Klarman Gives Insight on Keryx Biopharmaceuticals Investment Jan 26 2016 
Seth Klarman Blames Market, Investments for Rare Down Year Jan 25 2016 
David Abrams Buys Stake in Heavy Equipment Company Dec 15 2015 
Why Seth Klarman Keeps Buying Keryx Biopharma Nov 03 2015 
Seth Klarman Raises Position in Keryx Biopharmaceuticals Oct 21 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Is Seth Klarman right about Keryx Inc.? Jun 25 2015 
Seth Klarman Buys Pioneer Natural Resources, SunEdison Semiconductor Ltd, Atara Biotherapeutics Inc, May 15 2015 
Analysts Positive on Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data May 05 2015 

More From Other Websites
ETFs with exposure to Keryx Biopharmaceuticals, Inc. : December 5, 2016 Dec 05 2016
ETFs with exposure to Keryx Biopharmaceuticals, Inc. : November 23, 2016 Nov 23 2016
Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21,... Nov 21 2016
Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week Nov 18 2016
Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week Nov 18 2016
Keryx (KERX) Stock Up on Positive Phase III Auryxia Data Nov 18 2016
KERYX BIOPHARMACEUTICALS INC Financials Nov 17 2016
Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of... Nov 17 2016
Keryx (KERX) Q3 Loss Wider than Expected, Restores Supply Nov 10 2016
​FDA action helps Keryx move past drug supply snafu Nov 10 2016
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events Nov 09 2016
Edited Transcript of KERX earnings conference call or presentation 9-Nov-16 1:00pm GMT Nov 09 2016
ETF’s with exposure to Keryx Biopharmaceuticals, Inc. : November 9, 2016 Nov 09 2016
Keryx Biopharma upgraded by Maxim Group Nov 09 2016
Keryx Biopharmaceuticals Announces U.S. FDA Approval of Second Contract Manufacturer for Auryxia®... Nov 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)